SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Sodium/glucose cotransporter 2 (SGLT2) inhibitors, like dapagliflozin and empagliflozin, demonstrate improvements in liver dysfunction, steatosis, and fibrosis, emphasizing their potential as therapeutic agents for MASLD [144].